Xilio Therapeutics Announces Promotion of Martin Huber, MD, to President


Paul Clancy elected chairman of the board

Robert Ross, MD, appointed to the Board of Directors

WALTHAM, Mass., June 16, 2022 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people with cancer, announced today today promoted Martin Huber, MD, to President of Xilio. Dr. Huber will continue to lead research and development (R&D).

“I am delighted to announce the promotion of Marty to President of Xilio,” said René Russo, Pharm.D., Chief Executive Officer of Xilio. “Marty’s R&D and operational leadership will be instrumental in the continued growth and evolution of the company as we seek to advance our selective tumor immuno-oncology programs. »

In addition, Paul Clancy was elected chairman of Xilio’s board of directors, and Robert Ross, MD, chief executive officer of Surface Oncology, Inc., was named a member of the company’s board of directors. Mr. Clancy has served on Xilio’s board of directors since July 2020 and succeeds Dan Lynch, who previously served as chairman and who will become a strategic advisor to Xilio.

“Paul has played an important role on our Board of Directors over the past two years, bringing considerable knowledge of financial management and strategic business planning and execution in support of growth and development. evolution of Xilio,” Dr. Russo said. “I am very pleased that we continue to benefit from the deep industry expertise and leadership of Paul, now as Chairman of the Board. I would also like to thank Dan for his many contributions and invaluable perspective during a period in which Xilio has transitioned to both a publicly traded company and a clinical stage. »

Dr. Russo continued, “Rob is an accomplished medical oncologist with extensive experience leading oncology programs from discovery to clinical, and we welcome him to the board. Rob’s experience will be critical as we continue to advance our clinical programs and seek to leverage our platform to expand our pipeline.

Martin Huber, MD
Martin Huber, MD, a medical oncologist by training, brings more than 30 years of experience in clinical research and oncology drug development. Prior to becoming president of Xilio, Dr. Huber served as president of R&D and chief medical officer for the company. Prior to Xilio, he served as Senior Vice President and Chief Medical Officer at Tesaro, Inc. prior to its acquisition by GlaxoSmithKline plc. Prior to Tesaro, he served as Vice President of Clinical Oncology Research at Merck, where he was instrumental in advancing Merck’s oncology programs, serving as program manager for pembrolizumab in non-small cell lung cancer. Previously, Dr. Huber held various positions of increasing responsibility at Schering-Plough, Hoffman-La Roche and Rhône-Poulenc Rorer. Dr. Huber is a member of the board of directors of Mersana Therapeutics, Inc. and Syndax Pharmaceuticals, Inc. Dr. Huber earned a BS in Biology from Texas Lutheran College and an MD from Baylor College of Medicine. He completed his medical oncology training at UTMD Anderson Cancer Center.

Paul Clancy
Paul Clancy has served on Xilio’s Board of Directors since July 2020 and brings over 35 years of experience in financial management and strategic business planning. Mr. Clancy most recently served as Executive Vice President, Senior Advisor to Alexion Pharmaceuticals, Inc., and previously served as Alexion’s Chief Financial Officer. Prior to Alexion, Mr. Clancy served as Executive Vice President and Chief Financial Officer at Biogen Inc. Prior to Biogen, Mr. Clancy spent 13 years at PepsiCo Inc., holding various positions in finance, strategy and general management. Mr. Clancy is a member of the board of directors of Agios Pharmaceuticals, Inc., Incyte Corporation, Exact Sciences Corporation and Sionna Therapeutics, a private biotechnology company. Mr. Clancy is a Visiting Lecturer in Finance at the Cornell University Graduate School of Business. Mr. Clancy holds a Bachelor of Business Administration degree from Babson College and an MBA from Columbia Business School.

Robert Ross, MD
Robert Ross, MD, is the Chief Executive Officer and member of the Board of Directors of Surface Oncology, Inc. Dr. Ross previously served as Chief Medical Officer of Surface. Prior to Surface, Dr. Ross served as Chief Oncology Officer at bluebird bio, Inc. and previously served as Senior Vice President of Clinical Development and Pharmacovigilance and Vice President of Clinical Development. Prior to bluebird bio, Dr. Ross worked at Genentech and Infinity Pharmaceuticals, Inc. Dr. Ross was a medical oncology fellow and faculty member at the Dana Farber Cancer Institute (DFCI) from 2003 to 2007, then maintained training clinical practice at DFCI until 2015. Dr. Ross currently serves on the board of Obsidian Therapeutics, Inc., a private biotechnology company. Dr. Ross earned a BS in Biological Sciences and a BA in Philosophy from Stanford University, an MSc in Medical Science from Harvard Medical School, and an MD from Columbia University College of Physicians and Surgeons. He completed his residency in internal medicine at the University of California, San Francisco.

About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company focused on harnessing the immune system to achieve profound and lasting clinical answers to improve the lives of cancer patients. The company uses its proprietary Geographically Precise Solutions (GPS) platform to rapidly design new molecules, including cytokines and other biologics, designed to optimize their therapeutic index. These molecules are designed to localize activity to the tumor microenvironment without systemic effect, resulting in enhanced anti-tumor activity. Xilio is building a pipeline of GPS-enabled tumor-selective cytokine and checkpoint inhibitor product candidates, including its clinical-stage programs, XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody, and XTX202, an IL-2 selective anti-tumor, as well as its prior pipeline, including XTX301, a tumor-selective IL-12. For more information, please visit www.xiliotx.com and follow us on Twitter (@xiliotx) and LinkedIn (Xilio Therapeutics, Inc..).

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, timing and expectations relating to the progress of Xilio’s current or future product or program candidates; plans, timing and expectations related to the expansion of Xilio’s pipeline; the potential benefits of any of Xilio’s current or future product candidates in treating patients; and Xilio’s strategy, objectives and expected financial performance, milestones, business plans and direction. The words “aim”, “may”, “will”, “could”, “should”, “should”, “expect”, “plan”, “anticipate”, “intend”, ” believe”, “estimate”, “predict”, “project”, “potential”, “continue”, “seek”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain not these identifying words. All forward-looking statements contained in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and other important factors that could cause events or actual results differ materially from those expressed or implied by any forward-looking statement. the forward-looking statements contained in this press release, including, without limitation, risks and uncertainties relating to ongoing and planned research and development activities, including the initiation, conduct or completion of studies preclinical studies and clinical trials, as well as the timing and results of such preclinical studies or clinical trials; the delay of any ongoing or planned preclinical studies or clinical trials or the development of Xilio’s current or future product candidates; Xilio’s ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates; Xilio’s advancement of several start-up programs; Xilio’s ability to successfully demonstrate the safety and efficacy of its product candidates and to obtain approval of its product candidates in a timely manner, if at all; results of preclinical studies or clinical trials for Xilio’s product candidates, which may not support further development of such product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of current or future clinical trials; Xilio’s ability to obtain, maintain and enforce patent and other intellectual property protections for current or future product candidates; Xilio’s ability to obtain and maintain sufficient cash resources to fund current or future operating expenses and capital expenditure requirements; the impact of international trade policies on Xilio’s business, including the trade policies of the United States and China; and the impact of the COVID-19 pandemic on Xilio’s business, operations, strategy, objectives and planned milestones. These and other risks and uncertainties are described in greater detail in the sections titled “Summary of Risk Factors” and “Risk Factors” in Xilio’s filings with the Securities and Exchange Commission (SEC) of United States, including Xilio’s latest quarterly report on Form 10-Q. and any other filings Xilio has made or may make with the SEC in the future. All forward-looking statements contained in this press release represent the views of Xilio only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio expressly disclaims any obligation to update forward-looking statements.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

For investor inquiries:
Melissa Forest
Slang Partners

[email protected]

For media inquiries:
Julissa Viana
Vice President, Corporate Communications

[email protected]

main logo


About Author

Comments are closed.